Friday 5-16-2014 Biogen Idec Inc (BIIB) $BIIB open
Post# of 122
Posted On: 05/17/2014 12:27:38 PM
Friday 5-16-2014 Biogen Idec Inc (BIIB) $BIIB opened at 288.58 hitting the high price of 292.55 and a day low of 285.01 with a total volume of 1,148,100. BIIB had a previous close of 289.53 and has been seeing an average volume of 1,461,525.
Overall Average: 56% Sell
Recent stock forum discussions about BIIB http://investorshangout.com/search?q=BIIB&...mp;yt0=Go!
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - 1 hr 36 mins ago
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S.... (full story)
Why the Market Is Wrong About This Popular Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 27 mins ago
Few areas of disease treatment have captured investors' attention as fully as medical marijuana has this year. While medical marijuana dispensaries have grabbed the spotlight lately, there are also biotechs attempting to create life-enhancing... (full story)
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,... (full story)
Upcoming Conferences, Stock Price Movements and Support to Humanitarian Programs - Analyst Notes on Celgene, Biogen Idec, Incyte, Jazz Pharmaceuticals and Medivation
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free. (full story)
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free. (full story)
Is Isis Pharmaceuticals, Inc. Now a Bargain?
George Budwell, The Motley Fool - Motley Fool - Tue May 13, 11:31AM CDT
Isis Pharmaceuticals has one heck of a bad year in terms of the performance of its share price, falling close to 40% year-to-date. And starting in late February, the stock has essentially made a beeline lower. Given the dramatic and rapid nature of... (full story)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.85% Gain
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $288.01 to a high of $301.00. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $291.28 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Cisco Powers Up as Dow Races to Hundred-Point Gain
Dan Carroll, The Motley Fool - Motley Fool - Mon May 12, 1:35PM CDT
Stocks have raced higher to start the new week, with the Dow Jones Industrial Average jumping out of the starting gate at the bell and rising 110 points as of 2:30 p.m. EDT. Most blue-chip stocks on the index are in the green. Tech giant Cisco ... (full story)
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at: (full story)
Post Earnings Update: Biogen Idec Has Sunk 6.6% Lower in Past 2 Weeks (BIIB)
Comtex SmarTrend(R) - Mon May 12, 10:58AM CDT
When Biogen Idec (NASDAQ:BIIB) reported earnings 19 days ago on April 23rd, 2014, analysts, on average, expected the company to report earnings of $2.56 on sales of $2.0 billion. The company actually reported EPS of $2.47 on sales of $2.1 billion, missing EPS estimates by $0.08 and beating revenue estimates by $126.2 million. Shares of Biogen Idec have slipped from $306.75 to $286.65, representing a loss of 6.6%, since the company reported earnings 19 days ago. (full story)
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over. (full story)
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings. (full story)
Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Business Wire - Mon May 12, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine. (full story)
Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
Thomson Reuters ONE - Mon May 12, 1:19AM CDT
- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years - (full story)
Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World
Business Wire - Mon May 12, 1:00AM CDT
Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its efforts to raise the standard of care for people with hemophilia in the developing world. The remaining 5000 million IUs of clotting factor will be made available for future distribution. (full story)
3 Drugs Set to Become Blockbusters in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 10:30AM CDT
Blockbuster status, an unofficial gold medal awarded to therapies racking up sales of $1 billion or more per year, is the holy grail for drug developers. Arguably, it's the chance to discover blockbusters that fuel industry R&D spending and... (full story)
Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:20PM CDT
Infinity Pharma (INFI) reported a loss of 87 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 80 cents. (full story)
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which... (full story)
Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Thu May 08, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The webcast will be live on Wednesday, May 14, 2014 at 5:00 p.m. PT, 8:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation. (full story)
Overall Average: 56% Sell
Recent stock forum discussions about BIIB http://investorshangout.com/search?q=BIIB&...mp;yt0=Go!
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - 1 hr 36 mins ago
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S.... (full story)
Why the Market Is Wrong About This Popular Marijuana Stock
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 27 mins ago
Few areas of disease treatment have captured investors' attention as fully as medical marijuana has this year. While medical marijuana dispensaries have grabbed the spotlight lately, there are also biotechs attempting to create life-enhancing... (full story)
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,... (full story)
Upcoming Conferences, Stock Price Movements and Support to Humanitarian Programs - Analyst Notes on Celgene, Biogen Idec, Incyte, Jazz Pharmaceuticals and Medivation
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free. (full story)
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free. (full story)
Is Isis Pharmaceuticals, Inc. Now a Bargain?
George Budwell, The Motley Fool - Motley Fool - Tue May 13, 11:31AM CDT
Isis Pharmaceuticals has one heck of a bad year in terms of the performance of its share price, falling close to 40% year-to-date. And starting in late February, the stock has essentially made a beeline lower. Given the dramatic and rapid nature of... (full story)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.85% Gain
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $288.01 to a high of $301.00. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $291.28 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Cisco Powers Up as Dow Races to Hundred-Point Gain
Dan Carroll, The Motley Fool - Motley Fool - Mon May 12, 1:35PM CDT
Stocks have raced higher to start the new week, with the Dow Jones Industrial Average jumping out of the starting gate at the bell and rising 110 points as of 2:30 p.m. EDT. Most blue-chip stocks on the index are in the green. Tech giant Cisco ... (full story)
Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at: (full story)
Post Earnings Update: Biogen Idec Has Sunk 6.6% Lower in Past 2 Weeks (BIIB)
Comtex SmarTrend(R) - Mon May 12, 10:58AM CDT
When Biogen Idec (NASDAQ:BIIB) reported earnings 19 days ago on April 23rd, 2014, analysts, on average, expected the company to report earnings of $2.56 on sales of $2.0 billion. The company actually reported EPS of $2.47 on sales of $2.1 billion, missing EPS estimates by $0.08 and beating revenue estimates by $126.2 million. Shares of Biogen Idec have slipped from $306.75 to $286.65, representing a loss of 6.6%, since the company reported earnings 19 days ago. (full story)
Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over. (full story)
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings. (full story)
Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Business Wire - Mon May 12, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine. (full story)
Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
Thomson Reuters ONE - Mon May 12, 1:19AM CDT
- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years - (full story)
Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World
Business Wire - Mon May 12, 1:00AM CDT
Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its efforts to raise the standard of care for people with hemophilia in the developing world. The remaining 5000 million IUs of clotting factor will be made available for future distribution. (full story)
3 Drugs Set to Become Blockbusters in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 10:30AM CDT
Blockbuster status, an unofficial gold medal awarded to therapies racking up sales of $1 billion or more per year, is the holy grail for drug developers. Arguably, it's the chance to discover blockbusters that fuel industry R&D spending and... (full story)
Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:20PM CDT
Infinity Pharma (INFI) reported a loss of 87 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 80 cents. (full story)
Investor's Corner: How To Use The Big Cap 20
at Investor's Business Daily - Thu May 08, 3:09PM CDT
As IBD stock screens go, the IBD Big Cap 20 is of a different stripe. A primary focus on large-capitalization stocks distinguishes it from the high-growth slant of the IBD 50 or Your Weekly Review. But that doesn't mean that the IBD Big Cap 20, which... (full story)
Biogen Idec to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Thu May 08, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The webcast will be live on Wednesday, May 14, 2014 at 5:00 p.m. PT, 8:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation. (full story)
(0)
(0)Biogen Inc. (BIIB) Stock Research Links
Scroll down for more posts ▼